JP2019031568A5 - - Google Patents

Download PDF

Info

Publication number
JP2019031568A5
JP2019031568A5 JP2018208158A JP2018208158A JP2019031568A5 JP 2019031568 A5 JP2019031568 A5 JP 2019031568A5 JP 2018208158 A JP2018208158 A JP 2018208158A JP 2018208158 A JP2018208158 A JP 2018208158A JP 2019031568 A5 JP2019031568 A5 JP 2019031568A5
Authority
JP
Japan
Prior art keywords
composition
seq
cdr
antibody
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018208158A
Other languages
English (en)
Japanese (ja)
Other versions
JP6581279B2 (ja
JP2019031568A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2019031568A publication Critical patent/JP2019031568A/ja
Publication of JP2019031568A5 publication Critical patent/JP2019031568A5/ja
Application granted granted Critical
Publication of JP6581279B2 publication Critical patent/JP6581279B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018208158A 2013-10-08 2018-11-05 抗folr1免疫抱合体投薬レジメン Active JP6581279B2 (ja)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201361888365P 2013-10-08 2013-10-08
US201361888337P 2013-10-08 2013-10-08
US61/888,337 2013-10-08
US61/888,365 2013-10-08
US201461948363P 2014-03-05 2014-03-05
US61/948,363 2014-03-05
US201462004815P 2014-05-29 2014-05-29
US62/004,815 2014-05-29

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2016521270A Division JP6463744B2 (ja) 2013-10-08 2014-10-08 抗folr1免疫抱合体投薬レジメン

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019156399A Division JP2019218386A (ja) 2013-10-08 2019-08-29 抗folr1免疫抱合体投薬レジメン

Publications (3)

Publication Number Publication Date
JP2019031568A JP2019031568A (ja) 2019-02-28
JP2019031568A5 true JP2019031568A5 (enExample) 2019-08-08
JP6581279B2 JP6581279B2 (ja) 2019-09-25

Family

ID=52813740

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2016521270A Active JP6463744B2 (ja) 2013-10-08 2014-10-08 抗folr1免疫抱合体投薬レジメン
JP2018208158A Active JP6581279B2 (ja) 2013-10-08 2018-11-05 抗folr1免疫抱合体投薬レジメン
JP2019156399A Withdrawn JP2019218386A (ja) 2013-10-08 2019-08-29 抗folr1免疫抱合体投薬レジメン
JP2021125147A Active JP7386208B2 (ja) 2013-10-08 2021-07-30 抗folr1免疫抱合体投薬レジメン
JP2023192883A Pending JP2024016239A (ja) 2013-10-08 2023-11-13 抗folr1免疫抱合体投薬レジメン

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2016521270A Active JP6463744B2 (ja) 2013-10-08 2014-10-08 抗folr1免疫抱合体投薬レジメン

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2019156399A Withdrawn JP2019218386A (ja) 2013-10-08 2019-08-29 抗folr1免疫抱合体投薬レジメン
JP2021125147A Active JP7386208B2 (ja) 2013-10-08 2021-07-30 抗folr1免疫抱合体投薬レジメン
JP2023192883A Pending JP2024016239A (ja) 2013-10-08 2023-11-13 抗folr1免疫抱合体投薬レジメン

Country Status (29)

Country Link
US (3) US20150132323A1 (enExample)
EP (3) EP4424323A3 (enExample)
JP (5) JP6463744B2 (enExample)
KR (7) KR20240027861A (enExample)
CN (1) CN106164093A (enExample)
AU (4) AU2014331964C1 (enExample)
BR (1) BR112016007479A2 (enExample)
CA (1) CA2926325C (enExample)
CY (1) CY1122449T1 (enExample)
DK (2) DK3055332T3 (enExample)
ES (2) ES2983055T3 (enExample)
FI (1) FI3653228T3 (enExample)
HR (2) HRP20192140T1 (enExample)
HU (2) HUE046696T2 (enExample)
IL (4) IL313730A (enExample)
LT (2) LT3055332T (enExample)
MX (2) MX384973B (enExample)
MY (1) MY174670A (enExample)
NZ (2) NZ757964A (enExample)
PL (2) PL3055332T3 (enExample)
PT (2) PT3653228T (enExample)
RS (2) RS65798B1 (enExample)
RU (1) RU2696579C2 (enExample)
SG (3) SG10201907042PA (enExample)
SI (2) SI3653228T1 (enExample)
SM (1) SMT201900694T1 (enExample)
UA (1) UA119541C2 (enExample)
WO (1) WO2015054400A2 (enExample)
ZA (1) ZA201902009B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT201700139T1 (it) 2010-02-24 2017-05-08 Immunogen Inc Immunoconiugati contro il recettore 1 del folato e relativi usi
CN114441757A (zh) * 2011-04-01 2022-05-06 伊缪诺金公司 用于增加folr1癌症治疗的功效的方法
MX362514B (es) 2012-08-31 2019-01-22 Immunogen Inc Kits y ensayos de diagnostico para la deteccion del receptor 1 de folato.
KR20240068778A (ko) * 2013-05-14 2024-05-17 이뮤노젠 아이엔씨 항-folr1 면역접합체 투약 섭생
SG11201601037YA (en) 2013-08-30 2016-03-30 Immunogen Inc Antibodies and assays for detection of folate receptor 1
JP6880006B2 (ja) 2015-09-17 2021-06-02 イミュノジェン, インコーポレイテッド 抗folr1免疫複合体を含む治療組み合わせ
BR112019023909A8 (pt) * 2017-05-16 2023-04-11 Immunogen Inc Uso de um imunoconjugado que se liga a folr1, e, uso de um imunoconjugado que se liga a folr1 e pembrolizumab
AU2018333945B2 (en) 2017-09-18 2025-06-12 Sutro Biopharma, Inc. Anti- folate receptor alpha antibody conjugates and their uses
WO2019177854A1 (en) 2018-03-13 2019-09-19 Phanes Therapeutics, Inc. Anti-folate receptor 1 antibodies and uses thereof
JP7623939B2 (ja) 2018-07-09 2025-01-29 マルチチュード インコーポレーテッド 葉酸受容体アルファに特異的な抗体
KR20220004687A (ko) 2019-04-29 2022-01-11 이뮤노젠 아이엔씨 이중파라토프 fr-알파 항체 및 면역접합체
US20240226312A1 (en) * 2021-06-04 2024-07-11 Immunogen, Inc. Treatment of cancer in patients with soluble fr-alpha
EP4440625A1 (en) * 2021-12-01 2024-10-09 Sutro Biopharma, Inc. Anti-folate receptor conjugate cancer therapy
EP4455164A1 (en) * 2021-12-24 2024-10-30 Bio-Thera Solutions, Ltd. ANTI-FRalpha ANTIBODY, AND ANTIBODY-DRUG CONJUGATE AND USE THEREOF

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3896111A (en) 1973-02-20 1975-07-22 Research Corp Ansa macrolides
US4307016A (en) 1978-03-24 1981-12-22 Takeda Chemical Industries, Ltd. Demethyl maytansinoids
US4256746A (en) 1978-11-14 1981-03-17 Takeda Chemical Industries Dechloromaytansinoids, their pharmaceutical compositions and method of use
JPS55102583A (en) 1979-01-31 1980-08-05 Takeda Chem Ind Ltd 20-acyloxy-20-demethylmaytansinoid compound
JPS55162791A (en) 1979-06-05 1980-12-18 Takeda Chem Ind Ltd Antibiotic c-15003pnd and its preparation
JPS5645483A (en) 1979-09-19 1981-04-25 Takeda Chem Ind Ltd C-15003phm and its preparation
EP0028683A1 (en) 1979-09-21 1981-05-20 Takeda Chemical Industries, Ltd. Antibiotic C-15003 PHO and production thereof
JPS5645485A (en) 1979-09-21 1981-04-25 Takeda Chem Ind Ltd Production of c-15003pnd
WO1982001188A1 (en) 1980-10-08 1982-04-15 Takeda Chemical Industries Ltd 4,5-deoxymaytansinoide compounds and process for preparing same
US4450254A (en) 1980-11-03 1984-05-22 Standard Oil Company Impact improvement of high nitrile resins
US4313946A (en) 1981-01-27 1982-02-02 The United States Of America As Represented By The Secretary Of Agriculture Chemotherapeutically active maytansinoids from Trewia nudiflora
US4315929A (en) 1981-01-27 1982-02-16 The United States Of America As Represented By The Secretary Of Agriculture Method of controlling the European corn borer with trewiasine
US4563304A (en) 1981-02-27 1986-01-07 Pharmacia Fine Chemicals Ab Pyridine compounds modifying proteins, polypeptides or polysaccharides
JPS57192389A (en) 1981-05-20 1982-11-26 Takeda Chem Ind Ltd Novel maytansinoid
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6100064A (en) 1984-04-06 2000-08-08 Chiron Corporation Secreted viral proteins useful for vaccines and diagnostics
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
JP2938569B2 (ja) 1990-08-29 1999-08-23 ジェンファーム インターナショナル,インコーポレイティド 異種免疫グロブリンを作る方法及びトランスジェニックマウス
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
WO1992009690A2 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
WO1993011236A1 (en) 1991-12-02 1993-06-10 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
DE69231123T2 (de) 1992-03-25 2001-02-15 Immunogen Inc Konjugaten von Zell-bindender Mittel und Derivaten von CC-1065
ES2176484T3 (es) 1995-08-18 2002-12-01 Morphosys Ag Bancos de proteinas/(poli)peptidos.
US7264963B1 (en) 1995-08-18 2007-09-04 Morphosys Ag Protein(poly)peptide libraries
US6544787B1 (en) * 1996-11-15 2003-04-08 Hadash Medical Research Services And Development Ltd. Non-myeloablative/lymphoablative conditioning regimen to induce patient anti-donor unresponsiveness in stem cell transplantation
ATE482275T1 (de) 1999-07-02 2010-10-15 Morphosys Ag Erzeugung spezifischer bindungspartner die an von genomischen dns-fragmenten oder ests kodierten (poly)peptiden binden
US6333410B1 (en) 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
US20020151508A1 (en) * 2001-02-09 2002-10-17 Schering Corporation Methods for treating proliferative diseases
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
US6716821B2 (en) 2001-12-21 2004-04-06 Immunogen Inc. Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same
GB0202319D0 (en) 2002-02-01 2002-03-20 Calex Electronics Ltd Apparatus
US20080131366A1 (en) * 2003-03-17 2008-06-05 Manohar Ratnam Folate Receptor Gene Modulation For Cancer Diagnosis And Therapy
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
AU2005279347A1 (en) 2004-08-30 2006-03-09 Lonza Biologics Plc. Affinity- plus ion exchange- chromatography for purifying antibodies
WO2006105141A1 (en) * 2005-03-30 2006-10-05 Purdue Research Foundation Method for cancer prognosis using cellular folate vitamin receptor quantification
US20090162374A1 (en) * 2005-09-14 2009-06-25 Geraghty Daniel E Specific removal of activated immune cells
EP1900752A1 (en) * 2006-09-15 2008-03-19 DOMPE' pha.r.ma s.p.a. Human anti-folate receptor alpha antibodies and antibody fragments for the radioimmunotherapy of ovarian carcinoma
US7691980B2 (en) 2007-01-09 2010-04-06 Bio-Rad Laboratories, Inc. Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers
WO2009092014A1 (en) 2008-01-18 2009-07-23 Gagnon Peter S Enhanced purification of antibodies and antibody fragments by apatite chromatography
WO2009094456A2 (en) * 2008-01-22 2009-07-30 Johns Hopkins University Use of high-dose, post-transplantation oxazaphosphorine drugs for reduction of transplant rejection
CN104524592B (zh) 2008-04-30 2018-06-05 伊缪诺金公司 交联剂和它们的用途
CN102083461B (zh) 2008-04-30 2014-09-17 伊缪诺金公司 有效的偶联物和亲水性连接体
EA201100984A1 (ru) * 2008-12-19 2012-01-30 Грэйсуэй Фармасьютикалс, Ллс Композиции с более низким содержанием имиквимода и короткие режимы дозирования для лечения актинического кератоза
CN102630165A (zh) * 2009-10-21 2012-08-08 免疫基因公司 一种新的给药方案和治疗方法
SMT201700139T1 (it) * 2010-02-24 2017-05-08 Immunogen Inc Immunoconiugati contro il recettore 1 del folato e relativi usi
US8530122B2 (en) 2010-07-30 2013-09-10 Konica Minolta Business Technologies, Inc. Foil transferring face forming toner and image forming method
JP6224456B2 (ja) * 2010-11-05 2017-11-01 モルフォテック、インク. 葉酸受容体アルファ発現癌の診断および予後マーカーとしての葉酸受容体アルファ
CN114441757A (zh) * 2011-04-01 2022-05-06 伊缪诺金公司 用于增加folr1癌症治疗的功效的方法
US20120282282A1 (en) 2011-04-04 2012-11-08 Immunogen, Inc. Methods for Decreasing Ocular Toxicity of Antibody Drug Conjugates
MX362514B (es) * 2012-08-31 2019-01-22 Immunogen Inc Kits y ensayos de diagnostico para la deteccion del receptor 1 de folato.
EA032775B1 (ru) * 2013-04-08 2019-07-31 Берг Ллк Способы лечения злокачественной опухоли с использованием комбинированной терапии с коферментом q10
KR20240068778A (ko) * 2013-05-14 2024-05-17 이뮤노젠 아이엔씨 항-folr1 면역접합체 투약 섭생
SG11201601037YA (en) * 2013-08-30 2016-03-30 Immunogen Inc Antibodies and assays for detection of folate receptor 1
JP6880006B2 (ja) * 2015-09-17 2021-06-02 イミュノジェン, インコーポレイテッド 抗folr1免疫複合体を含む治療組み合わせ

Similar Documents

Publication Publication Date Title
JP2019031568A5 (enExample)
JP2020519675A5 (enExample)
JP2025129187A5 (enExample)
HRP20192140T1 (hr) Režimi doziranja anti-folr1 imunokonjugata
US20250289880A1 (en) Use of anti-fam19a5 antibodies for treating cancers
JP2016534039A5 (enExample)
JP2018527383A5 (enExample)
RU2018111205A (ru) Терапевтические комбинации, содержащие анти-folr1 иммуноконъюгаты
RU2019141270A (ru) Комбинации анти-folr1 иммуноконъюгатов и анти-pd-1 антител
AU2018261080A1 (en) Stable formulations of anti-TIGIT antibodies alone and in combination with programmed death receptor 1 (PD-1) antibodies and methods of use thereof
JP2021501776A5 (enExample)
IL312038A (en) Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer
JP2020508317A5 (enExample)
JP2020514310A5 (enExample)
FI3394103T3 (fi) Anti-PD-1-vasta-aineiden ja bispesifisten anti-CD20-/anti-CD3-vasta-aineiden yhdistelmä syövän hoitoon
JP2016520082A5 (enExample)
JP2017536341A5 (enExample)
KR20160138177A (ko) 항-egfr 항체 및 항체 약물 접합체
FI3810281T3 (fi) Menetelmiä syövän hoitamiseksi bispesifisillä anti-CD3XMUC16-vasta-aineilla ja anti-PD-1-vasta-aineilla
JP2013520442A5 (enExample)
BR112020016986A2 (pt) formulações de anticorpo contra b7-h4
JP2010520290A5 (enExample)
IL278400B1 (en) Combination of an anti-PD-1 antibody and conjugation of a drug with an anti-TF antibody for use in the treatment of cancer
JP2016525560A5 (enExample)
JPWO2018213260A5 (enExample)